» Articles » PMID: 17667943

Expression and Sequence Analysis of Candidates for the 1p36.31 Tumor Suppressor Gene Deleted in Neuroblastomas

Overview
Journal Oncogene
Date 2007 Aug 2
PMID 17667943
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2 Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. We sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. However, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.

Citing Articles

The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.

Galiger C, Zohora F, Dorneburg C, Tews D, Debatin K, Beltinger C BMC Cancer. 2023; 23(1):1148.

PMID: 38007466 PMC: 10676583. DOI: 10.1186/s12885-023-11635-2.


Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.

Wang H, Wang X, Xu L Ital J Pediatr. 2023; 49(1):145.

PMID: 37904225 PMC: 10617224. DOI: 10.1186/s13052-023-01549-x.


Clinical value of F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma.

Ren J, Fu Z, Zhao Y Front Oncol. 2023; 13:1099290.

PMID: 37035169 PMC: 10079884. DOI: 10.3389/fonc.2023.1099290.


Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.

Xu L, Shao F, Luo T, Li Q, Tan D, Tan Y Int J Mol Sci. 2022; 23(15).

PMID: 35955624 PMC: 9369136. DOI: 10.3390/ijms23158489.


mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.

Heidari Z, Asemi-Rad A, Moudi B, Mahmoudzadeh-Sagheb H J Int Med Res. 2022; 50(7):3000605221105344.

PMID: 35808817 PMC: 9274423. DOI: 10.1177/03000605221105344.